Whitehawk Therapeutics Q3 2026 Results: Net Loss of $21.2M, Loss Widens
Whitehawk Therapeutics reported a net loss of $60.0 million for the nine months ended September 30, 2026, compared to a net income of $2.7 million in the prior year period, which had been bolstered by an $87.3 million gain on the sale of a business. The company ended the quarter with $169.7 million in cash, cash equivalents, and short-term investments following a private placement that raised approximately $81.7 million in net proceeds.
- Key figure
- Net loss $21.2M